Loading
Genscript Biotech Corporation Stock: price and insider trades · Hong Kong
No insider purchase over the last 90 days. The latest, by Meng Jiange, was filed 10 Jun 2026.
Insider Decl.
459
Thresholds
n/a
Buy Volume
€216M
52 ops. · all time
Sell Volume
€477M
133 ops. · all time
Who traded when
BuySaleWang Luquan12 sales
Zhu Li2 buys10 sales
Shao Weihui2 buys6 sales
Meng Jiange1 buy5 sales
Dai Zumian2 sales
Grossman Ross2 buys
+3 other insiders
Since the insiders bought
- +184.5%Entry HK$11.84 · Close at T+90 HK$33.68
- +184.5%Entry HK$11.84 · Close at T+90 HK$33.68
- +184.5%Entry HK$11.84 · Close at T+90 HK$33.68
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Genscript Biotech Corporation Strong Buy (bullish), based on 6 analysts. Average price target: HK$32.95.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 20,063 of 26,248 companies
33.3
score / 100
Value35
Quality32
FCF yld0.3%
Earn yld-0.7%
EV/EBITDA·
ROE-15%
Gross mgn58%
Net mgn-56%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
HK$33.64
Analyst consensus
6 analystsStrong buy
HK$15.92Target HK$32.95(-2%)HK$42.64
Income statement
RevenueHK$959.5M
Gross profitHK$553.2M58% margin
EBITDA-HK$379.2M-40% margin
Net income-HK$532.8M-75.4% margin
Valuation
PER (forward)672.8x
P/Book2.4x
Beta0.81
Balance sheet & cash
Market capHK$76.7B
Total debtHK$258.8M
Free Cash FlowHK$241.7M
Debt / Equity9%
Profitability & ownership
ROE-15.3%
ROA1.5%
% insiders35.2%
% institutions31.3%
Last declaration on 7 September 2026
Declarations459 total
1,737 shares@ HK$35.74480.0001% mcap1.3% of flowShareXHKGHKEX:DA20260904E00486
32,883 shares@ HK$35.93330.0012% mcap23.8% of flowShareXHKGHKEX:DA20260904E00485
155,535 shares@ HK$35.74480.0056% mcap58.0% of flowShareXHKGHKEX:DA20260904E00490
34,000 shares@ HK$33.180.0011% mcap22.6% of flowShareXHKGHKEX:DA20260821E00331
98,085 shares@ HK$26.07980.0026% mcap51.6% of flowShareXHKGHKEX:DA20260821E00330
14,208,034 sharesShareXHKGHKEX:DA20260625E00336
3,907,209 sharesShareXHKGHKEX:DA20260625E00322
7,693,304 sharesShareXHKGHKEX:DA20260625E00320
5,270,879 sharesShareXHKGHKEX:DA20260625E00318
313,650 shares@ HK$12.12060.0062% mcap39.9% of flowShareXHKGHKEX:DA20260609E00352
169,561 sharesShareXHKGHKEX:DA20260609E00356
Canonical exit: 2 Sept 2026 (T+90)
113,041 sharesShareXHKGHKEX:DA20260609E00362
Canonical exit: 2 Sept 2026 (T+90)
113,041 sharesShareXHKGHKEX:DA20260609E00361
Canonical exit: 2 Sept 2026 (T+90)
841,470 sharesShareXHKGHKEX:DA20260609E00353
Canonical exit: 2 Sept 2026 (T+90)
113,041 sharesShareXHKGHKEX:DA20260609E00347
Canonical exit: 2 Sept 2026 (T+90)
3,029 shares@ HK$12.12060.0001% mcap0.7% of flowShareXHKGHKEX:DA20260609E00348
16,071 shares@ HK$12.25080.0003% mcap2.1% of flowShareXHKGHKEX:DA20260410E00415
41,906 shares@ HK$12.37690.5% of flowShareXHKGHKEX:DA20260105E00537
13,010 shares@ HK$12.37690.8% of flowShareXHKGHKEX:DA20260105E00530
18,157 sharesShareXHKGHKEX:DA20251218E00303
Canonical exit: 15 Mar 2026 (T+90)
18,157 sharesShareXHKGHKEX:DA20251218E00307
Canonical exit: 15 Mar 2026 (T+90)
62,863 shares@ HK$17.27035.2% of flowShareXHKGHKEX:DA20251119E00214
683,788 sharesShareXHKGHKEX:DA20250924E00271
Canonical exit: 18 Dec 2025 (T+90)
115,538 shares@ HK$17.354410.2% of flowShareXHKGHKEX:DA20250905E00397
4,553,320 sharesShareXHKGHKEX:DA20250801E00261
25 of 459 declarations
About Genscript Biotech Corporation
The three directors Wang Ye, Wang Luquan and Zhang Fangliang appear together in the largest transactions at Genscript Biotech Corporation. On June 11, 2021, a sale of EUR 122,034,972 is filed under the name of Wang Luquan and under that of Wang Ye. On September 22, 2020, a purchase of EUR 839,142 appears under all three names. From September 1 to September 24, 2020, 9 different filers bought. Wang Ye also sold EUR 42,945,899 on June 7, 2018.
The record holds 459 filings from 15 filers. Sales number 227, worth EUR 1.19 billion with a median of EUR 2,249,569, against 62 purchases, only 15 of them with an amount, EUR 5.2 million (median EUR 312,892): 21% purchases among open-market trades. Wang Ye is the top filer, with 116 filings, including 55 sales and 7 purchases; Wang Luquan has 106 and Zhang Fangliang 105. Besides these, 170 filings are of another kind.
Read moreShow less
A Chinese health care company listed in Hong Kong with a market capitalisation of HKD 76.7 billion, in which insiders hold 35.2% of the capital. Last twelve months: 22 filings, 7 purchases, 11 sales. All filings together: median delay of 3 days. For 23 purchases, the stored 90-day result is a median of minus 2.7%, with 22% positive: recorded past results, not a forecast.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
